Rubius Therapeutics Equity 2024

Rubius Therapeutics Aktienanalyse

What does Rubius Therapeutics do?

Rubius Therapeutics Inc is a US biotechnology company founded in 2013. The company's goal is to develop therapies based on artificially manufactured red blood cells, known as RBCs, to treat diseases for which effective treatment methods are currently unavailable. The idea for the creation of Rubius began with a discovery by Dr. Aviv Regev at the Broad Institute, a research institute in Cambridge, Massachusetts. She discovered a method for using artificially manufactured red blood cells to treat diseases. Rubius was launched to intensify research and development in this area and create groundbreaking therapies using a new technology. Rubius has a unique business model. The company relies on a novel development platform that focuses not on delivering drugs into cells, but on using red blood cells as a base. The technology enables the incorporation of special proteins or active ingredients into the RBCs' membrane. By selectively releasing these active ingredients into the bloodstream, diseases can be directly treated at their source. This approach offers many advantages, such as increased effectiveness and reduced side effects. Rubius is currently working on several product candidates in various clinical research programs. The company has three main areas of focus: immunology, rare diseases, and cancer. In the field of immunology, they are developing therapies for autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The company also has a pipeline of products that can be used for rare blood disorders like hemophilia. Additionally, Rubius is involved in cancer immunotherapy, aiming to combat cancer cells by targeted activation of the immune system. Rubius Therapeutics has already achieved successes, such as the approval of an RBC-based drug for sickle cell disease by the US Food and Drug Administration (FDA) in spring 2020. The first target molecule on the RBC surface refers to the C5b9 membrane attack complex, which can cause damage to red blood cells, inflammation, and damage to blood vessels. Rubius aims to incorporate a specific protein into the artificial red blood cells that blocks the attack on red blood cells by the C5b9 membrane attack complex. As a leader in the biotechnology industry, Rubius is an innovative company with a novel business model and promising technology. It is shaping the industry with various developments and revolutionizing therapy for serious diseases that previously lacked satisfactory treatment methods. Overall, Rubius is a promising company with great potential for the future. Rubius Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Rubius Therapeutics's Equity

Rubius Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Rubius Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Rubius Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Rubius Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Rubius Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Rubius Therapeutics Stock

What is the equity of Rubius Therapeutics this year?

Rubius Therapeutics has equity of 15.1 M USD this year.

What was the equity of Rubius Therapeutics compared to the previous year?

The equity of Rubius Therapeutics has increased/decreased by -91.55% decreased compared to the previous year.

What impact does a high equity have on investors of Rubius Therapeutics?

A high equity is advantageous for investors of Rubius Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Rubius Therapeutics?

A low equity can be a risk for investors of Rubius Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Rubius Therapeutics affect the company?

An increase in equity of Rubius Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Rubius Therapeutics affect the company?

A reduction in equity of Rubius Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Rubius Therapeutics?

Some factors that can affect the equity of Rubius Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Rubius Therapeutics so important for investors?

The equity of Rubius Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Rubius Therapeutics take to change the equity?

To change equity, Rubius Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Rubius Therapeutics pay?

Over the past 12 months, Rubius Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rubius Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Rubius Therapeutics?

The current dividend yield of Rubius Therapeutics is .

When does Rubius Therapeutics pay dividends?

Rubius Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rubius Therapeutics?

Rubius Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Rubius Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rubius Therapeutics located?

Rubius Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rubius Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rubius Therapeutics from 12/29/2023 amounting to 0.058 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2024.

When did Rubius Therapeutics pay the last dividend?

The last dividend was paid out on 12/29/2023.

What was the dividend of Rubius Therapeutics in the year 2023?

In the year 2023, Rubius Therapeutics distributed 0 USD as dividends.

In which currency does Rubius Therapeutics pay out the dividend?

The dividends of Rubius Therapeutics are distributed in USD.